Docking of cationic antibiotics to negatively charged pockets in RNA folds.

The binding of aminoglycosides to RNA provides a paradigm system for the analysis of RNA-drug interactions. The electrostatic field around three-dimensional RNA folds creates localized and defined negatively charged regions which are potential docking sites for the cationic ammonium groups of aminoglycosides. To explore in RNA folds the electronegative pockets suitable for aminoglycoside binding, we used calculations of the electrostatic field and Brownian dynamics simulations of cation diffusion. We applied the technique on those RNA molecules experimentally known to bind aminoglycosides, namely, two tobramycin aptamers (Wang, Y.; Rando, R. R. Chem. Biol. 1995, 2, 281-290): the aminoglycoside-binding region in 16S ribosomal RNA (Moazed, S.; Noller, H. F. Nature 1987, 327, 389-394) and the TAR RNA from human immunodeficiency virus (Mei, H.-Y.; et al. Bioorg. Med. Chem. Lett. 1995, 5, 2755-2760). For the aptamers and ribosomal RNA, for which the binding sites of the aminoglycosides are known, a good agreement between negatively charged pockets and the binding positions of the drugs was found. On the basis of variations between neomycin-like and kanamycin-like aminoglycosides in the interaction with the electrostatic field of ribosomal RNA, we propose a model for the different binding specificities of these two classes of drugs. The spatial congruence between the electronegative pockets in RNA folds and binding positions of aminoglycosides was used to dock aminoglycosides to ribosomal and TAR RNAs. Molecular dynamics simulations were used to analyze possible RNA-drug interactions. Aminoglycosides inhibit the binding of the viral Tat protein to TAR RNA; however, the drug-binding sites are still unknown. Thus, our docking approach provides first structural models for TAR-aminoglycoside complexes. The RNA-drug interactions observed in the modeled complexes support the view that the antibiotics might lock TAR in a conformation with low affinity for the Tat protein, explaining the experimentally found aminoglycoside inhibition of the Tat-TAR interaction (Mei, H.-Y.; et al. Bioorg. Med. Chem. Lett. 1995, 5, 2755-2760).

[1]  W. Wilson,et al.  Design and analysis of RNA structure‐specific agents as potential antivirals , 1996, Journal of molecular recognition : JMR.

[2]  J. Puglisi,et al.  Binding of neomycin-class aminoglycoside antibiotics to the A-site of 16 S rRNA. , 1998, Journal of molecular biology.

[3]  Y Wang,et al.  Specificity of aminoglycoside binding to RNA constructs derived from the 16S rRNA decoding region and the HIV-RRE activator region. , 1997, Biochemistry.

[4]  K. Flaherty,et al.  Three-dimensional structure of a hammerhead ribozyme , 1994, Nature.

[5]  W. Wilson,et al.  Design and analysis of molecular motifs for specific recognition of RNA. , 1997, Bioorganic & medicinal chemistry.

[6]  Michael J. Gait,et al.  Methylphosphonate mapping of phosphate contacts critical for RNA recognition by the human immunodeficiency virus tat and rev proteins , 1994, Nucleic Acids Res..

[7]  O. Uhlenbeck,et al.  Role of divalent metal ions in the hammerhead RNA cleavage reaction. , 1991, Biochemistry.

[8]  S. Yokoyama,et al.  An antibiotic-binding motif of an RNA fragment derived from the A-site-related region of Escherichia coli 16S rRNA. , 1996, Nucleic acids research.

[9]  Dinshaw J. Patel,et al.  Structure, recognition and adaptive binding in RNA aptamer complexes. , 1997, Journal of molecular biology.

[10]  A. Ellington,et al.  In vitro selection of RNA lectins: using combinatorial chemistry to interpret ribozyme evolution. , 1995, Chemistry & biology.

[11]  M. Guéron,et al.  Significance and mechanism of divalent-ion binding to transfer RNA. , 1982, Biophysical journal.

[12]  D. P. Mack,et al.  INHIBITION OF AN HIV-1 TAT-DERIVED PEPTIDE BINDING TO TAR RNA BY AMINOGLYCOSIDE ANTIBIOTICS , 1995 .

[13]  A. W. Czarnik,et al.  Inhibitors of protein-RNA complexation that target the RNA: specific recognition of human immunodeficiency virus type 1 TAR RNA by small organic molecules. , 1998, Biochemistry.

[14]  T. Klimkait,et al.  A new class of HIV-1 Tat antagonist acting through Tat-TAR inhibition. , 1998, Biochemistry.

[15]  E Westhof,et al.  RNA as a drug target: chemical, modelling, and evolutionary tools. , 1998, Current opinion in biotechnology.

[16]  J. Killian,et al.  Minimal RNA constructs that specifically bind aminoglycoside antibiotics with high affinities. , 1998, Biochemistry.

[17]  J. Davies,et al.  Structure-Activity Relationships Among the Aminoglycoside Antibiotics: Role of Hydroxyl and Amino Groups , 1973, Antimicrobial Agents and Chemotherapy.

[18]  S. Stern,et al.  Interactions of a small RNA with antibiotic and RNA ligands of the 30S subunit , 1994, Nature.

[19]  Dinshaw J. Patel,et al.  Solution structure of the tobramycin–RNA aptamer complex , 1998, Nature Structural Biology.

[20]  C. Prescott,et al.  RNA as a drug target. , 1997, Chemistry & biology.

[21]  Patel,et al.  Molecular recognition in the bovine immunodeficiency virus Tat peptide-TAR RNA complex. , 1995, Chemistry & biology.

[22]  Harry F. Noller,et al.  Interaction of antibiotics with functional sites in 16S ribosomal RNA , 1987, Nature.

[23]  B. Stoddard,et al.  Capturing the Structure of a Catalytic RNA Intermediate: The Hammerhead Ribozyme , 1996, Science.

[24]  J. Karn,et al.  Structure of HIV-1 TAR RNA in the absence of ligands reveals a novel conformation of the trinucleotide bulge. , 1996, Nucleic acids research.

[25]  R. Rando,et al.  Specific binding of aminoglycoside antibiotics to RNA. , 1995, Chemistry & biology.

[26]  G. Gish,et al.  Phosphorothioates in molecular biology. , 1989, Trends in biochemical sciences.

[27]  H. Schneider,et al.  A Cationic Cyclophane That Forms a Base-Pair Open Complex with RNA Duplexes , 1996 .

[28]  T. Steitz,et al.  Metals, Motifs, and Recognition in the Crystal Structure of a 5S rRNA Domain , 1997, Cell.

[29]  J. Puglisi,et al.  rRNA chemical groups required for aminoglycoside binding. , 1998, Biochemistry.

[30]  D M Crothers,et al.  Equilibrium binding of magnesium(II) by Escherichia coli tRNAfMet. , 1976, Biochemistry.

[31]  C. Wong,et al.  Specificity of aminoglycoside antibiotics for the A-site of the decoding region of ribosomal RNA. , 1998, Chemistry & biology.

[32]  W. Hillen,et al.  Visualizing metal-ion-binding sites in group I introns by iron(II)-mediated Fenton reactions. , 1998, Chemistry & biology.

[33]  W D Wilson,et al.  The search for structure-specific nucleic acid-interactive drugs: effects of compound structure on RNA versus DNA interaction strength. , 1993, Biochemistry.

[34]  Chi‐Huey Wong,et al.  Probing the Specificity of Aminoglycoside−Ribosomal RNA Interactions with Designed Synthetic Analogs , 1998 .

[35]  J. Doudna,et al.  Metal-binding sites in the major groove of a large ribozyme domain. , 1996, Structure.

[36]  E. Westhof,et al.  Deciphering RNA recognition: aminoglycoside binding to the hammerhead ribozyme. , 1998, Chemistry & biology.

[37]  J. Davies,et al.  Antibiotic inhibition of group I ribozyme function , 1991, Nature.

[38]  J L Sussman,et al.  RNA-ligant interactions. (I) Magnesium binding sites in yeast tRNAPhe. , 1977, Nucleic acids research.

[39]  Klaus Gundertofte,et al.  A comparison of conformational energies calculated by several molecular mechanics methods , 1996, J. Comput. Chem..

[40]  E Westhof,et al.  Restrained refinement of two crystalline forms of yeast aspartic acid and phenylalanine transfer RNA crystals. , 1987, Acta crystallographica. Section A, Foundations of crystallography.

[41]  E Westhof,et al.  Isoalloxazine derivatives promote photocleavage of natural RNAs at G.U base pairs embedded within helices. , 1997, Nucleic acids research.

[42]  Y Wang,et al.  RNA molecules that specifically and stoichiometrically bind aminoglycoside antibiotics with high affinities. , 1996, Biochemistry.

[43]  P. Kollman,et al.  A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .

[44]  O. Uhlenbeck,et al.  Divalent metal ions and the internal equilibrium of the hammerhead ribozyme. , 1995, Biochemistry.

[45]  J. Karn,et al.  An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[46]  A Klug,et al.  A crystallographic study of metal-binding to yeast phenylalanine transfer RNA. , 1977, Journal of molecular biology.

[47]  B. Coxon,et al.  Nitrogen-15 nuclear magnetic resonance spectroscopy of neomycin B and related aminoglycosides , 1983 .

[48]  A. Frankel,et al.  HIV-1: fifteen proteins and an RNA. , 1998, Annual review of biochemistry.

[49]  E. Westhof,et al.  Exploration of metal ion binding sites in RNA folds by Brownian-dynamics simulations. , 1998, Structure.

[50]  A. W. Czarnik,et al.  Binding of neomycin to the TAR element of HIV-1 RNA induces dissociation of Tat protein by an allosteric mechanism. , 1998, Biochemistry.

[51]  O. Uhlenbeck,et al.  Inhibition of the hammerhead ribozyme by neomycin. , 1969, RNA.

[52]  E. Westhof,et al.  Aminoglycoside binding to the hammerhead ribozyme: a general model for the interaction of cationic antibiotics with RNA. , 1998, Journal of molecular biology.

[53]  Christine S. Chow,et al.  A Structural Basis for RNA−Ligand Interactions , 1997 .

[54]  R. Schroeder,et al.  In vitro selection and characterization of streptomycin-binding RNAs: recognition discrimination between antibiotics. , 1998, RNA.

[55]  Tao Pan,et al.  12 Divalent Metal Ions in RNA Folding and Catalysis , 1993 .

[56]  A. Hüttenhofer,et al.  In vitro selection analysis of neomycin binding RNAs with a mutagenized pool of variants of the 16S rRNA decoding region. , 1996, Biochemistry.

[57]  D. P. Mack,et al.  Discovery of selective, small-molecule inhibitors of RNA complexes--I. The Tat protein/TAR RNA complexes required for HIV-1 transcription. , 1997, Bioorganic & medicinal chemistry.

[58]  J. Karn,et al.  The structure of the human immunodeficiency virus type-1 TAR RNA reveals principles of RNA recognition by Tat protein. , 1995, Journal of molecular biology.

[59]  J. Puglisi,et al.  Structure of the A Site of Escherichia coli 16S Ribosomal RNA Complexed with an Aminoglycoside Antibiotic , 1996, Science.

[60]  Lead cleavage sites in the core structure of group I intron-RNA. , 1993, Nucleic acids research.

[61]  Z. Wang,et al.  RNA-protein interactions in the Tat-trans-activation response element complex determined by site-specific photo-cross-linking. , 1998, Biochemistry.

[62]  W. Saenger,et al.  DNA—Ligand Interactions , 1987, NATO ASI Series.

[63]  K. Sharp,et al.  Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons , 1991, Proteins.

[64]  L. Brakier-Gingras,et al.  Streptomycin binds to the decoding center of 16 S ribosomal RNA. , 1997, Journal of molecular biology.

[65]  Y. Tor,et al.  Electrostatic Interactions in RNA Aminoglycosides Binding , 1997 .

[66]  J Grasby,et al.  Hydrogen-bonding contacts in the major groove are required for human immunodeficiency virus type-1 tat protein recognition of TAR RNA. , 1993, Journal of molecular biology.

[67]  R. Schroeder,et al.  Interaction of Aminoglycoside Antibiotics with RNA , 1996 .

[68]  Michael R. Green,et al.  Small molecules that selectively block RNA binding of HIV-1 rev protein inhibit rev function and viral production , 1993, Cell.

[69]  Christine S. Chow,et al.  A Structural Basis for RNA-Ligand Interactions , 1997 .

[70]  R Cedergren,et al.  Modeling RNA-ligand interactions: the Rev-binding element RNA-aminoglycoside complex. , 1998, Journal of medicinal chemistry.

[71]  J. Puglisi,et al.  Paromomycin binding induces a local conformational change in the A-site of 16 S rRNA. , 1998, Journal of molecular biology.

[72]  A. Klug,et al.  Pb(II)-catalysed cleavage of the sugar–phosphate backbone of yeast tRNAPhe—implications for lead toxicity and self-splicing RNA , 1983, Nature.

[73]  J. Puglisi,et al.  RNA sequence determinants for aminoglycoside binding to an A-site rRNA model oligonucleotide. , 1996, Journal of molecular biology.

[74]  W. Krzyzosiak,et al.  Identification of the magnesium, europium and lead binding sites in E. coli and lupine tRNAPhe by specific metal ion‐induced cleavages , 1989, FEBS letters.

[75]  J. Puglisi,et al.  Solution Structure of a Bovine Immunodeficiency Virus Tat-TAR Peptide-RNA Complex , 1995, Science.

[76]  D. Patel,et al.  Saccharide-RNA recognition in an aminoglycoside antibiotic-RNA aptamer complex. , 1997, Chemistry & biology.

[77]  O. Uhlenbeck,et al.  Neomycin inhibition of the hammerhead ribozyme involves ionic interactions. , 1995, Biochemistry.

[78]  M. Famulok,et al.  A novel RNA motif for neomycin recognition. , 1995, Chemistry & biology.

[79]  H. Noller.  Ribosomal RNA and translation. , 1991, Annual review of biochemistry.

[80]  R. Schroeder,et al.  Inhibition of the self-cleavage reaction of the human hepatitis delta virus ribozyme by antibiotics. , 1996, Journal of molecular biology.